Hypoxia augments MHC class I antigen presentation via facilitation of ERO1‐α‐mediated oxidative folding in murine tumor cells |
| |
| Authors: | Toshimitsu Kajiwara Tsutomu Tanaka Kazuharu Kukita Goro Kutomi Keita Saito Koichi Okuya Akari Takaya Vitaly Kochin Takayuki Kanaseki Tomohide Tsukahara Yoshihiko Hirohashi Toshihiko Torigoe Koichi Hirata Noriyuki Sato Yasuaki Tamura |
| |
| Affiliation: | 1. Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan;2. Department of Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan;3. Department of Molecular Therapeutics, Center for Food and Medical Innovation, Institute for the Promotion of Business and Regional Collaboration, Hokkaido University, Sapporo, Japan |
| |
| Abstract: | To establish an effective cancer immunotherapy, it is crucial that cancer cells present a cancer‐specific antigen in a hypoxic area, a hallmark of the tumor microenvironment. Here, we show the impact of hypoxia on MHC class I antigen presentation in vitro and in vivo in murine tumors. Activation of antigen‐specific CTLs by tumor cells that had been pre‐incubated under a condition of hypoxia was enhanced compared with that by tumor cells pre‐incubated under a condition of normoxia. Cell surface expression of MHC class I‐peptide complex on the tumor cells was increased under a condition of hypoxia, thereby leading to higher susceptibility to specific CTLs. We show that the hypoxia‐inducible ER‐resident oxidase ERO1‐α plays an important role in the hypoxia‐induced augmentation of MHC class I‐peptide complex expression. ERO1‐α facilitated oxidative folding of MHC class I heavy chains, thereby resulting in the augmentation of cell surface expression of MHC class I‐peptide complex under hypoxic conditions. These results suggest that since the expression of MHC class I‐peptide complex is augmented in a hypoxic tumor microenvironment, strategies for inhibiting the function of regulatory T cells and myeloid‐derived suppressor cells and/or immunotherapy with immune checkpoint inhibitors are promising for improving cancer immunotherapy. |
| |
| Keywords: | Cancer immunity Disulfide bond Hypoxia MHC class I molecule Oxidoreductase |
|
|
